Top neuro stories of December: Sunlight may lower MS risk in kids, FDA approves Vyvgart

Healio Neurology’s five most-viewed stories in December highlight a study on increased sun exposure lowering children’s MS risk, FDA approval of a treatment for myasthenia gravis and research on a self-administered examination that may quickly identify mild cognitive impairment conversion to dementia.

Kids who get more sunlight may have lower risk for MS

Increased sunlight exposure may offer significant protection against development of pediatric MS, according to study results published in Neurology. Read more.

FDA approves Vyvgart for treatment of myasthenia gravis

The FDA announced the approval of Vyvgart for treatment of the chronic autoimmune, neuromuscular disease myasthenia gravis in adults who are positive for acetylcholine receptor antibody. Read more.

Self-administered exam more quickly identifies MCI conversion to dementia

A self-administered test detected mild cognitive impairment conversion to dementia at least 6 months sooner than the Mini-Mental State Examination, according to results of a cohort study published in Alzheimer’s Research & Therapy. Read more.

Patients with MS at increased risk for prolonged COVID-19 symptoms

Post-acute sequelae of COVID-19 impacted nonhospitalized patients with MS, according to results of a prospective and longitudinal cohort study published in Neurology: Neuroimmunology & Neuroinflammation. Read more.

Many mild cognitive impairment cases appear to resolve over time

Nearly 50% of individuals with incident mild cognitive impairment diagnoses were considered cognitively normal at follow-up, according to results of a community-based cohort study published in Neurology. Read more.